Thermo Fisher beats by $0.02, reports revs in-line; reaffirms FY16 EPS guidance, slighly lowers and guides FY16 revs in-line
- Reports Q2 (Jun) earnings of $2.03 per share, $0.02 better than the Capital IQ Consensus of $2.01; revenues rose 6.2% year/year to $4.54 bln vs the $4.49 bln Capital IQ Consensus.
- Life Sciences Solutions Segment - In the second quarter of 2016, Life Sciences Solutions Segment revenue grew 13% to $1.28 billion, compared with revenue of $1.13 billion in the second quarter of 2015. Segment operating margin was 28.9% versus 28.6% in 2015.
- Analytical Instruments Segment - Analytical Instruments Segment revenue increased 2% to $794 million in the second quarter of 2016, compared with revenue of $777 million in the second quarter of 2015. Segment operating margin was 18.3% versus 18.0% in the 2015 quarter.
- Specialty Diagnostics Segment - Specialty Diagnostics Segment revenue in the second quarter increased 4% to $851 million in 2016, compared with revenue of $817 million in the second quarter of 2015. Segment operating margin was 27.9% versus 27.8% in the 2015 quarter.
- Laboratory Products and Services Segment - In the second quarter of 2016, Laboratory Products and Services Segment revenue grew 6% to $1.80 billion, compared with revenue of $1.69 billion in the second quarter of 2015. Segment operating margin was 15.5% versus 15.4% in the 2015 quarter.
- Co issues guidance for FY16, sees EPS of $8.07-8.20 vs. $8.13 Capital IQ Consensus Estimate and versus prior guidance of $8.05 to $8.19; sees FY16 revs of $17.84-18.00 bln vs. $17.95 bln Capital IQ Consensus Estimate and versus its prior guidance of $17.86-18.04 bln.